CLINICAL TRIALS PROFILE FOR DEFERASIROX

505(b)(2) Clinical Trials for deferasirox

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
New Formulation	NCT02435212 ↗	Study to Evaluate Treatment Compliance, Efficacy and Safety of an Improved Deferasirox Formulation (Granules) in Pediatric Patients (2-	Active, not recruiting	Novartis Pharmaceuticals	Phase 2	2015-10-21	This is a randomized, open-label, multicenter, two arm, phase II study to evaluate treatment compliance and change in serum ferritin of a deferasirox granule formulation and a deferasirox DT formulation in children and adolescents aged ≥ 2 and < 18 years at enrollment with any transfusion-dependent anemia requiring chelation therapy due to iron overload, to demonstrate the effect of improved compliance on iron burden. Randomization will be stratified by age groups (2 to

All Clinical Trials for deferasirox

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00061750 ↗	Safety & Efficacy of ICL670 vs. Deferoxamine in Beta-thalassemia Patients With Iron Overload Due to Blood Transfusions	Completed	Novartis Pharmaceuticals	Phase 3	2003-05-01	The purpose of this study is to deterimine if the new orally active iron chelator, ICL670, is as effective and as safe as deferoxamine in preventing accumulation of iron in the body while a patient is undergoing repeated blood transfusions.
NCT00061763 ↗	Study of Deferasirox in Iron Overload From Beta-thalassemia Unable to be Treated With Deferoxamine or Chronic Anemias	Completed	Novartis Pharmaceuticals	Phase 2	2003-05-01	The purpose of this study is to determine the effects of the oral iron chelator Deferasirox on liver iron content after one year of treatment in patients with iron overload from repeated blood transfusions. Beta-thalassemia patients unable to be treated with deferoxamine or patients with rare chronic anemias such as Myelodysplastic Syndrome, Fanconi's Syndrome, Blackfan-Diamond Syndrome, and Pure Red Blood Cell Anemia are eligible for this study. Liver iron content will be measured by liver biopsy at the beginning of the study and after one year of treatment. However, those patients living in the San Francisco/Oakland area may have a SQUID in place of the liver biopsy if the biopsy is not medically possible for them. The SQUID is a non-invasive magnetic means to measure liver iron content.
NCT00067080 ↗	Safety of ICL670 vs. Deferoxamine in Sickle Cell Disease Patients With Iron Overload Due to Blood Transfusions	Completed	Novartis Pharmaceuticals	Phase 2	2003-05-01	The purpose of this study is to determine if the new orally active iron chelator, ICL670, is as safe as deferoxamine in preventing accumulation of iron in the body while a patient is undergoing repeated blood transfusions.
NCT00110266 ↗	Study of Deferasirox for Treatment of Transfusional Iron Overload in Myelodysplastic Patients	Completed	Novartis Pharmaceuticals	Phase 2	2005-07-25	The purpose of this trial is to examine the safety and efficacy of deferasirox in patients with Myelodysplastic Syndrome (MDS) and chronic iron overload from blood transfusions.
NCT00110617 ↗	Study of Deferasirox Relative to Subcutaneous Deferoxamine in Sickle Cell Disease Patients	Completed	Novartis Pharmaceuticals	Phase 2	2005-05-01	This study will examine the long-term safety and efficacy of Deferasirox in patients with sickle cell disease and iron overload from repeated blood transfusions.
NCT00117507 ↗	Study for the Treatment of Transfusional Iron Overload in Myelodysplastic Patients	Completed	Novartis Pharmaceuticals	Phase 4	2005-09-01	Thirty patients were to be enrolled and 24 patients were actually enrolled into this open-label, single-arm trial designed to assess the safety and tolerability of oral deferasirox in adult transfusion dependent myelodysplastic syndrome (MDS) patients with iron overload. Patients enrolled in this study had low or intermediate (INT-1) risk MDS per International Prognostic Scoring System (IPSS) criteria. All patients initiated treatment with 20mg/kg/day deferasirox. Deferasirox were administered orally once per day for 12 months.
NCT00171171 ↗	A Study of Long-term Treatment With Deferasirox in Patients With Beta-thalassemia and Transfusional Hemosiderosis	Completed	Novartis	Phase 3	2004-05-01	Because patients with beta-thalassemia are unable to actively eliminate iron from the body, toxic and eventually lethal levels of iron can accumulate as a result of repeated blood transfusions. This study will evaluate the efficacy, safety and tolerability of deferasirox.

Clinical Trial Conditions for deferasirox

Condition Name

Condition Name for deferasirox
Intervention	Trials
Iron Overload	16
Myelodysplastic Syndromes	12
Transfusional Iron Overload	7
Beta-thalassemia	7

Condition MeSH

Condition MeSH for deferasirox
Intervention	Trials
Iron Overload	53
Thalassemia	37
beta-Thalassemia	26
Preleukemia	25

Clinical Trial Locations for deferasirox

Trials by Country

Trials by Country for deferasirox
Location	Trials
United States	208
Italy	71
Canada	21
China	20
United Kingdom	19

Trials by US State

Trials by US State for deferasirox
Location	Trials
California	23
New York	18
Illinois	15
Pennsylvania	14
Texas	12

Clinical Trial Progress for deferasirox

Clinical Trial Phase

Clinical Trial Phase for deferasirox
Clinical Trial Phase	Trials
PHASE2	3
Phase 4	21
Phase 3	11

Clinical Trial Status

Clinical Trial Status for deferasirox
Clinical Trial Phase	Trials
Completed	63
Terminated	14
Unknown status	11

Clinical Trial Sponsors for deferasirox

Sponsor Name

Sponsor Name for deferasirox
Sponsor	Trials
Novartis Pharmaceuticals	52
Novartis	11
Soroka University Medical Center	2

Sponsor Type

Sponsor Type for deferasirox
Sponsor	Trials
Other	92
Industry	69
NIH	5

Deferasirox: Clinical Trials Update, Market Analysis and 2030 Projections

Last updated: April 27, 2026

What clinical-trial readouts exist for deferasirox?

Deferasirox (oral iron chelator; brands include Exjade and Jadenu) is a mature asset with an established clinical package across iron overload indications. In 2023–2024, the main activity in the publicly visible record has been incremental rather than transformative, centered on operational updates (recruitment/completion for ongoing studies) and refinements by regimen or population rather than new fundamental mechanisms.

Core clinical development themes (high-level)

Deferasirox development is anchored in:

• Transfusional iron overload (primarily transfusion-dependent beta-thalassemia and similar populations)
• Non-transfusion-dependent iron overload (select populations with documented iron excess where chronic chelation is used)
• Secondary iron overload (e.g., chronic hemopathies and other causes)

Clinical evidence has historically supported safety and efficacy endpoints used by regulators:

• Reduction in serum ferritin
• Improvement or stabilization in liver iron concentration (commonly MRI-based in newer studies)
• Safety monitoring (renal function, hepatic transaminases, GI tolerability, and monitoring for adverse events consistent with chelation)

How to interpret “updates” in a mature chelator landscape

For mature chelators like deferasirox, clinical-trial “updates” tend to be:

• Completion/recruitment timing changes for ongoing studies rather than new efficacy readouts
• Population-specific validations (age strata, baseline iron status bands, comorbidity strata)
• Formulation-administration comparisons (where relevant)

Actionable implication: For investors and partners, the near-term value signal is more likely to come from label expansions tied to population criteria and real-world adherence/monitoring rather than from new Phase 3 readouts that reset the competitive landscape.

What is the market for deferasirox today?

Market positioning

Deferasirox addresses chronic iron overload, where long-duration therapy drives recurring demand. Competition includes other oral chelators and, in some geographies, parenteral chelation options. In practice, switching depends on:

• Renal and hepatic tolerability
• Dosing convenience and formulation preference
• Monitoring workflow and patient adherence

Pricing and reimbursement dynamics

Market pricing is driven by:

• WAC versus net pricing by country and payer
• Formulary placement (especially in thalassemia programs)
• Generic penetration and patent expiry timelines by jurisdiction

Deferasirox also benefits from being entrenched in treatment guidelines and clinical workflows, which reduces switching risk once a payer has established monitoring pathways.

Competition set (commercial)

Key comparators commonly include:

• Deferiprone (oral alternative)
• Deferoxamine (parenteral, sometimes used where oral options fail or are not tolerated)
• Other regional oral chelators depending on market access and approvals

Generic and biosimilar-style dynamics

For a small-molecule chelator, the analogue to “platform competition” is generic entry:

• Lower-cost alternatives pressure gross pricing
• Net price erosion depends on which molecules are granted sustained formulary access
• Brand loyalty can persist where brand-specific formulations support adherence and monitoring

Actionable implication: The market is best modeled as a mix of (1) enduring patient demand and (2) pricing erosion tied to generic intensity and formulary switching.

What is the 2025–2030 market projection for deferasirox?

Projection logic

For deferasirox, a robust projection is typically decomposed into:

1. Addressable population trajectory in transfusional and non-transfusional iron overload settings
2. Treatment persistence (how many patients stay on chelation year over year)
3. Price/mix drift from brand to generic and between chelation modalities
4. Access growth where national thalassemia programs expand screening and monitoring
5. Competitive switching based on tolerability and monitoring burdens

Base-case directional projection

Given the maturity of deferasirox and the long-cycle nature of iron overload therapy:

• Volume demand is expected to be stable to modestly growing in line with population and diagnosis/surveillance improvements.
• Revenue growth is expected to be constrained by price erosion, with total market value tracking modestly upward or flat depending on how aggressively payers substitute to generics.

2030 scenario framework (revenue CAGR style)

A defensible business model is scenario-based:

Base case (most likely):

• Volume: steady growth
• Net price: continues gradual erosion
• Revenue: low single-digit CAGR

Upside case:

• More consistent guideline adherence and/or favorable reimbursement retention for deferasirox
• Faster uptake in additional compliant patient subgroups
• Revenue: mid single-digit CAGR

Downside case:

• Intensified generic substitution across major markets
• Greater patient switching to alternative chelators due to tolerability perceptions or payer preference
• Revenue: flat to negative CAGR

Which clinical and regulatory variables can move the business?

1) Renal and hepatic safety profile management

Deferasirox requires ongoing monitoring. Even when the drug is clinically effective, payer and prescriber confidence can hinge on:

• Real-world adverse event rates
• Monitoring adherence (labs and renal function checks)
• Dose adjustments and patient management protocols

2) Treatment persistence and adherence

Oral chelators reduce infusion burden, but adherence depends on:

• Dosing schedule complexity
• GI tolerability
• Patient education and follow-up intensity

3) Formulation preference and switching economics

Where branded versus generic formulation differences matter (e.g., dose convenience, tolerability), patients can remain on a preferred version longer, reducing substitution speed.

4) Evidence-based guideline positioning

Deferasirox holds baseline guideline status in iron chelation. Changes in guideline recommendations or clinical pathway revisions can affect:

• Relative share versus deferiprone
• Uptake in earlier or later stages of iron overload

What does the competitive map look like by chelation modality?

Oral vs parenteral

Deferasirox competes primarily in the oral chelator space, where switching is common when patients face tolerability, monitoring constraints, or payer preference. Parenteral deferoxamine retains niche use depending on:

• patient tolerance
• infusion logistics
• acute or severe management needs where oral alternatives are not tolerated

Implications for share

For deferasirox, the strongest share risk is not loss of efficacy. It is:

• net pricing under generic penetration
• monitoring burden and real-world tolerability perception versus oral alternatives
• payer protocol placement (step therapy or formulary clustering)

Investment and partnership lens: what is actionable now?

1) Deferasirox remains a cash-flow anchor

For investors, deferasirox is better treated as a near-term revenue platform rather than a late-stage R&D thesis.

2) Key diligence targets

Focus diligence on:

• Market share by geography and formulary status
• Net price trends and expected generic substitution rate
• Real-world discontinuation patterns and adverse event-driven switches

3) The “trial update” value

Because deferasirox is mature, most trial updates do not change fundamental competitive dynamics. The business relevance is:

• whether new subgroups expand labeled utilization
• whether dosing regimen changes improve persistence
• whether safety monitoring advances reduce discontinuations

Key Takeaways

• Deferasirox is a mature iron chelator with clinical activity dominated by incremental updates rather than new transformative Phase 3 outcomes.
• The market is driven by chronic, long-duration therapy, with revenue shaped more by net price erosion from generics and payer formulary dynamics than by new clinical efficacy breakthroughs.
• 2025–2030 revenue growth is most plausibly low single-digit or flat-to-modest positive in base case scenarios, with upside tied to sustained formulary positioning and tighter adherence-driven persistence.

FAQs

1) What are the main indications that drive deferasirox demand?

Transfusion-dependent iron overload (including beta-thalassemia and similar transfusion-dependent settings) and select non-transfusion-dependent iron overload populations.

2) What are the main endpoints used in deferasirox trials?

Serum ferritin reduction and liver iron concentration trends (often via MRI in modern protocols), alongside safety monitoring of renal and hepatic function and tolerability.

3) What is the primary business risk for deferasirox?

Net price erosion from generic substitution and payer preference shifts to competing chelators.

4) Does deferasirox have meaningful competitive differentiation?

Differentiation is largely tied to oral administration, dosing convenience, tolerability management, and established monitoring pathways rather than a novel mechanism.

5) What is the most likely 2030 revenue trajectory?

A base-case path of low single-digit revenue CAGR or near-flat growth, contingent on how quickly generics compress net pricing and on persistence/adherence.

---

References

[1] U.S. FDA. Drug approvals and labeling for Exjade (deferasirox) and Jadenu (deferasirox). FDA database.
[2] EMA. European public assessment reports and product information for deferasirox products (Exjade/Jadenu). European Medicines Agency.
[3] ClinicalTrials.gov. Deferasirox clinical studies (registry entries). National Library of Medicine.